Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...

All patients were evaluated by the same urticaria specialist at a single tertiary care center during routine clinical practice. None had received prior omalizumab treatment. The study was approved by ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

With unfortunately no curative therapy for chronic spontaneous urticaria (CSU) available for now, the overall goal is to ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and ...

Certain chronic types of urticaria may require different medications, particularly if the trigger is physical rather than allergic. Some of these include: While many complementary and alternative ...

CSU is typically treated with H1 antihistamines, medicines that target H1 receptors on cells to control symptoms of urticaria. However, the disease remains uncontrolled despite antihistamine ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...